Immunomedics

Immunomedics is a biopharmaceutical company that specializes in the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other serious diseases. The company's advanced proprietary technologies allow it to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioisotopes, chemotherapeutics, or toxins, to create highly targeted agents.

History

Immunomedics was founded in 1982 by David M. Goldenberg, a pioneer in the field of radioimmunotherapy. The company's initial focus was on the development of monoclonal antibody-based imaging agents, but it soon expanded its research and development efforts to include therapeutic applications of its technologies.

Products and Pipeline

Immunomedics' product portfolio includes a number of monoclonal antibodies that are in various stages of clinical development. The company's lead product, Sacituzumab Govitecan, is a first-in-class antibody-drug conjugate that has shown promise in the treatment of several types of solid tumors.

In addition to Sacituzumab Govitecan, Immunomedics has several other products in its pipeline, including Labetuzumab Govitecan, a second antibody-drug conjugate that is currently in Phase II clinical trials for the treatment of colorectal cancer.

Research and Development

Immunomedics' research and development efforts are focused on the discovery and development of novel monoclonal antibodies and antibody-drug conjugates for the treatment of cancer and other serious diseases. The company's proprietary technologies, including its Dock-and-Lock (DNL) platform, allow it to create highly specific and potent therapeutic agents.

See Also

• Monoclonal antibodies
• Antibody-drug conjugate
• Cancer immunotherapy
• Radioimmunotherapy

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!